Marco Foppoli

Request an appointment

Specialty:

Hematology Hematology and Bone Marrow Transplantation in Adults Oncology

Profession:

Hematologist

Location:

Department of Haematology and Bone Marrow Transplantation @ Ospedale San Raffaele

Languages:

Request an appointment

Biography

Dr. Marco Foppoli heads the Functional Department of Oncohematology in the Department of Oncohematology, an integral part of the Department of Hematology and Bone Transplantation of the IRCCS Ospedale San Raffaele under the supervision of Professor Fabio Ciceri.

He is also responsible for inpatient clinical activities in the Lymphoma department of the same institute.

After graduating from the Milan State University in Medicine and Surgery in 1985, he received a specialization in 1988 in clinical and laboratory hematology at the same institute.

After 15 years of working as a therapist at the Department of Internal Medicine under the guidance of Professor Claudio Rugarli, Dr. Foppoli has been engaged in diagnostics, therapy and follow-up (outpatient and inpatient) for about 15 years, with special emphasis on lymphomas, chronic lymphocytic leukemia and multiple myeloma in both traditional and extended treatment (high-dose chemoimmunotherapy, autograft, allograft).

In addition, he is engaged in the diagnosis, clinical management and follow-up of platelet disorders in the periphery and in the center.

Marco Foppoli also coordinates complex patients from the clinical point of view of a comprehensive specialist therapist on the path of his interdisciplinary research.

From a research point of view, he manages numerous protocols of clinical, diagnostic studies, as well as research in terms of treatment, including with innovative molecules in phase 1. He is also involved in therapeutic protocols with CAR-T.

He is the author and co-author of numerous articles published in scientific journals. He constantly participates in national and international congresses, courses and conferences.

Education

University of Milan
Bachelor's Degree in Medicine and Surgery - 1985

University of Milan
Specialization in clinical and laboratory hematology - 1988

Do you need an appointment?

Request an appointment

Publications

Latest publications

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma.

Blood. 2019 Jul 18;134(3):252-262. doi:10.1182/blood.2019000633. Epub 2019 May 22

Ferreri AJM, Calimeri T, Conte GM, Cattaneo D, Fallanca F, Ponzoni M, Scarano E, Curnis F, Nonis A, Lopedote P, Citterio G, Politi LS, Foppoli M, Girlanda S, Sassone M, Perrone S, Cecchetti C, Ciceri F, Bordignon C, Corti A, Anzalone N.

Interleukin-1 Receptor Blockade Rescues Myocarditis- Associated End-Stage Heart Failure.

Front Immunol. 2017 Feb 9;8:131. doi:10.3389/fimmu.2017.00131. eCollection 2017

Cavalli G, Foppoli M, Cabrini L, Dinarello CA, Tresoldi M, Dagna L.

Primary Cardiac Lymphoma in an Immunocompetent 71- Year-Old Man.

Tex Heart Inst J. 2015 Dec 1;42(6):561-4. doi: 10.14503/THIJ-14-4269. eCollection 2015 Dec

Montanaro C, Loiacono F, Fragasso G, De Cobelli F, Foppoli M, Margonato A.

High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem- Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.

J Clin Oncol. 2015 Nov 20;33(33):3903-10. doi: 10.1200/JCO.2015.61.1236. Epub 2015 Aug 17

Ferreri AJ, Donadoni G, Cabras MG, Patti C, Mian M, Zambello R, Tarella C, Di Nicola M, D'Arco AM, Doa G, Bruno-Ventre M, Assanelli A, Foppoli M, Citterio G, Fanni A, Mulè A, Caligaris-Cappio F, Ciceri F.

Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.

Br J Haematol. 2015 Mar;168(5):654-62. doi: 10.1111/bjh.13194. Epub 2014 Oct 14.

Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, Vignati A, Scarfò L, Sassone M, Govi S, Caligaris-Cappio F.

Gamma-delta t-cell lymphomas

Eur J Haematol. 2015 Mar;94(3):206-18. doi:10.1111/ejh.12439. Epub 2014 Oct 1

Foppoli M, Ferreri AJ.

The primary mediastinal lymphoma: state of the art and therapeutical perspectives.

Recenti Prog Med. 2013 May;104(5):203-8. doi:10.1701/1291.14277. Review

Foppoli M, Citterio G, Donadoni G, Govi S, Ferreri AJ.

Cardiac involvement by non-Hodgkin's lymphoma in an HIV-positive patient with hypertrophic obstructive cardiomyopathy.

Recenti Prog Med. 2012 Dec;103(12):575-7. doi:10.1701/1206.13359

Demarchi B, Foppoli M, Contri R, Margonato A.

Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexatebased chemotherapy

Hematol Oncol. 2013 Sep;31(3):143-50. doi:10.1002/hon.2037. Epub 2012 Nov 14

Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Sorarù M, Vianello F, Baldini L, Proserpio I, Foppoli M, Assanelli A, Reni M, Caligaris-Cappio F, Ferreri AJ.

Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma.

Br J Haematol. 2012 Oct;159(2):252-5. doi:10.1111/bjh.12020. Epub 2012 Aug 25.

Ferreri AJ, Bruno Ventre M, Donadoni G, Cattaneo C, Fumagalli L, Foppoli M, Mappa S, Govi S, Di Nicola M, Rossi G, Tirelli U, Caligaris-Cappio F, Spina M, Re A.

Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination.

Oncologist. 2011;16(3):336-41. doi: 10.1634/theoncologist.2010-0361. Epub 2011 Feb 23

Ferreri AJ, Licata G, Foppoli M, Corazzelli G, Zucca E, Stelitano C, Zaja F, Fava S, Paolini R, Franzin A, Politi LS, Ponzoni M, Reni M.

Treatment approaches for primary CNS lymphomas.

Expert Opin Pharmacother. 2010 Jun;11(8):1263-76. doi: 10.1517/14656561003767456. Review

Carrabba MG, Reni M, Foppoli M, Chiara A, Franzin A, Politi LS, Villa E, Ciceri F, Ferreri AJ.

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

Lancet. 2009 Oct 31;374(9700):1512-20. doi: 10.1016/S0140-6736(09)61416-1. Epub 2009 Sep 18

Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F;International Extranodal Lymphom

Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate.

Cancer Lett. 2007 Dec 18;258(2):165-70. Epub 2007 Nov 13. Review

Reni M, Mazza E, Foppoli M, Ferreri AJ.

MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.

Neurology. 2006 May 9;66(9):1435-8

Ferreri AJ, Dell'Oro S, Foppoli M, Bernardi M, Brandes AA, Tosoni A, Montanari M, Balzarotti M, Spina M, Ilariucci F, Zaja F, Stelitano C, Bobbio F, Corazzelli G, Baldini L, Ponzoni M, Picozzi P, Caligaris Cappio F, Reni M.

Do you need an appointment?

Request an appointment